• Veracyte outlined plans to launch the Prosigna LDT on June 8, 2026, targeting ER+/HER2- breast cancer patients.
• Management framed the eligible US population at about 225,000 newly diagnosed ER+/HER2- breast cancer cases annually.
• The presentation highlighted OPTIMA as supporting Prosigna-directed chemotherapy decisions in a broad high-risk patient group.
• Prosigna clinical evidence base cited 157 breast-related publications, described as growing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Veracyte Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.